Music Therapy for impulsivity in Parkinson’s Disease: a clinical trial

Effect of Music Therapy on Inhibitory Control in Parkinson's Disease: a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-95ptyjx

Enrollment

Registered

2026-03-04

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inhibition, Psychological Parkinson Disease

Interventions

This is a randomized controlled clinical trial with two groups: intervention and control, with an estimated total sample of 40 participants, 20 in each group. Participants will be organized in an enum

that is, the interventionist will not have access to the evaluation outcomes until data collection is completed. There will be no blinding regarding allocation to the intervention and control groups.

Eligibility

Inclusion criteria

Inclusion criteria: Participants with an established diagnosis of idiopathic Parkinson’s disease; at stages one to three on the Hoehn and Yahr scale; with a score equal to or greater than 24 on the Montreal Cognitive Assessment (MoCA); of both sexes

Exclusion criteria

Exclusion criteria: Participants diagnosed with other neurological disorders; visual and/or auditory deficits that compromise the understanding and performance of the activities; and participants who are currently receiving therapeutic treatment for cognitive disorders

Design outcomes

Primary

Measure	Time frame
Evaluate participants’ inhibitory control using standardized psychological assessments, namely the Stroop Color-Word Test (SCWT), Go/No-Go Task, Hayling Test, and Barratt Impulsiveness Scale (BIS-11). The primary outcome will be defined by statistically significant improvements in inhibitory control measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments	—

Measure

Time frame

Evaluate participants’ inhibitory control using standardized psychological assessments, namely the Stroop Color-Word Test (SCWT), Go/No-Go Task, Hayling Test, and Barratt Impulsiveness Scale (BIS-11). The primary outcome will be defined by statistically significant improvements in inhibitory control measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments

—

Secondary

Measure	Time frame
Evaluate participants’ quality of life using a standardized psychological assessment, namely the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39). We will examine statistically significant improvements in quality of life measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments;Evaluate participants’ motor outcomes using a standardized clinical assessment, namely the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). We will examine statistically significant improvements in motor measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments;Evaluate participants’ cognitive outcomes using a standardized psychological assessment, namely the Montreal Cognitive Assessment (MoCA). We will examine statistically significant improvements in cognitive measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments	—

Measure

Time frame

Evaluate participants’ quality of life using a standardized psychological assessment, namely the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39). We will examine statistically significant improvements in quality of life measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments;Evaluate participants’ motor outcomes using a standardized clinical assessment, namely the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). We will examine statistically significant improvements in motor measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments;Evaluate participants’ cognitive outcomes using a standardized psychological assessment, namely the Montreal Cognitive Assessment (MoCA). We will examine statistically significant improvements in cognitive measures (p less than 0.05), accompanied by at least a moderate effect size (Cohen’s d greater than or equal to 0.5), in the comparison between pre- and post-intervention assessments

—

Countries

Contacts

Public ContactSimone Ramos

Universidade Federal do Paraná - Ciências Humanas e Sociais

simone.cristina@ufpr.br+55-41-33605094

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Apr 4, 2026